Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6856 to 6870 of 7691 results

  1. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

    Technology appraisal guidance
    Discontinued

  2. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued [GID-TA11256]

    Technology appraisal guidance
    Discontinued

  3. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued [GID-TAG384]

    Technology appraisal guidance
    Discontinued

  4. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued [GID-TA11257]

    Technology appraisal guidance
    Discontinued

  5. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued [GID-TAG376]

    Technology appraisal guidance
    Discontinued

  6. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued [GID-TA10722]

    Technology appraisal guidance
    Discontinued

  7. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued [GID-TA11258]

    Technology appraisal guidance
    Discontinued

  8. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued [GID-TAG389]

    Technology appraisal guidance
    Discontinued

  9. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued [GID-TA10138]

    Technology appraisal guidance
    Discontinued

  10. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development [GID-TA10882] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development [GID-TA11272] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Conjunctivitis: antimicrobial prescribing

    Discontinued [GID-NG10166]

    Antimicrobial prescribing guideline
    Discontinued

  13. Stye: antimicrobial prescribing

    Discontinued [GID-NG10167]

    Antimicrobial prescribing guideline
    Discontinued

  14. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

    Technology appraisal guidance
    Discontinued

  15. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued [GID-TA10767]

    Technology appraisal guidance
    Discontinued